15 Blue Street
Suite 503 Level 5
North Sydney, NSW 2060
Australia
61 2 9223 3344
https://www.oncosil.com.au
Sector(s):
Industry:
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Nigel Lange | CEO, MD & Director | 388.2k | N/A | N/A |
Mr. Michael Warrener | Global Sales & Marketing Director | N/A | N/A | N/A |
Dr. David Charles James | Global Head of Manufacturing Operations | N/A | N/A | N/A |
Dr. Ralph Peters | Chief Medical Officer | N/A | N/A | N/A |
Mr. David Turner | Head of Medical Affairs | N/A | N/A | N/A |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
OncoSil Medical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.